Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.56 |
| ▸ | GSTK1 | Q9Y2Q3 | 2/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.53 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adipic Acid SCHEMBL9811797 | 0.97 | TSHR (0.63) | LMNANFKB1TSHRPMP22FFAR4 | |
| Adipic Acid SCHEMBL6361755 | 0.97 | TSHR (0.63) | LMNANFKB1TSHRPMP22FFAR4 | |
| SCHEMBL16140282 | 0.97 | TSHR (0.63) | LMNANFKB1TSHRPMP22FFAR4 | |
| SCHEMBL7860210 | 0.97 | TSHR (0.63) | LMNANFKB1TSHRPMP22FFAR4 | |
| SCHEMBL5926323 | 0.97 | TSHR (0.63) | LMNANFKB1TSHRPMP22FFAR4 | |
| SCHEMBL11809460 | 0.97 | TSHR (0.63) | LMNANFKB1TSHRPMP22FFAR4 | |
| SCHEMBL17477592 | 0.97 | TSHR (0.63) | LMNANFKB1TSHRPMP22FFAR4 | |
| SCHEMBL1258357 | 0.92 | — | — | |
| SCHEMBL6746328 | 0.91 | FFAR4 (0.59) | LMNANFKB1TSHRPMP22FFAR4 | |
| Adipic Acid SCHEMBL630307 | 0.89 | FFAR4 (0.74) | TSHRFFAR4FFAR1SLC22A6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2591040-B1 | ALKYD RESIN | PERSTORP AB (SE) | 2019-08-14 | — | — | EP | claimed |
| WO-2017048169-A1 | PROCESS FOR PRODUCING A WATER DISPERSIBLE, AIR DRYING COATING BINDER | PERSTORP AB (SE) | 2017-03-23 | — | — | WO | claimed |
| EP-2591039-A1 | BRANCHED POLYESTER | Perstorp AB (SE) | 2013-05-15 | — | — | EP | claimed |
| EP-2591040-A1 | ALKYD RESIN | Perstorp AB (SE) | 2013-05-15 | — | — | EP | claimed |
| CN-102382054-A | Parazole and isoxazole derivative, preparation method for same and application thereof | UNIV PLA 2ND MILITARY MEDICAL | 2012-03-21 | — | — | CN | claimed |
| WO-2012005645-A1 | ALKYD RESIN | PERSTORP AB (SE) | 2012-01-12 | — | — | WO | claimed |
| WO-2012005648-A1 | UNSATURATED OLIGIO OR POLYESTER | PERSTORP AB (SE) | 2012-01-12 | — | — | WO | claimed |
| WO-2012005647-A1 | BRANCHED POLYESTER | PERSTORP AB (SE) | 2012-01-12 | — | — | WO | claimed |
| US-20260077032-A1 | KARI Nanoparticle | LA JOLLA INSTITUTE FOR IMMUNOLOGY (US) | 2026-03-19 | — | — | US | disclosed |
| EP-3599853-B1 | HERBICIDAL COMPOSITIONS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2025-07-30 | — | — | EP | disclosed |
| WO-2024006532-A2 | KARI NANOPARTICLE | LA JOLLA INSTITUTE FOR IMMUNOLOGY (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023159064-A1 | HERBICIDAL FORMULATIONS | INVAIO SCIENCES, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| EP-3470482-B1 | COATING COMPOSITION | JOTUN AS (NO) | 2023-07-26 | — | — | EP | disclosed |
| CN-113594465-B | Negative electrode binder and preparation method and application thereof | 苏州清陶新能源科技有限公司 | 2023-02-28 | — | — | CN | disclosed |
| WO-2009085953-A2 | KETOL-ACID REDUCTOISOMERASE USING NADH | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163376-A1 | KETOL-ACID REDUCTOISOMERASE USING NADH | E.I. DU PONT DE NEMOURS AND COMPANY | 2009-06-25 | — | — | US | disclosed |
| WO-2008130995-A2 | FERMENTIVE PRODUCTION OF ISOBUTANOL USING HIGHLY ACTIVE KETOL-ACID REDUCTOISOMERASE ENZYMES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080261230-A1 | FERMENTIVE PRODUCTION OF ISOBUTANOL USING HIGHLY ACTIVE KETOL-ACID REDUCTOISOMERASE ENZYMES | GEVO, INC. | 2008-10-23 | — | — | US | disclosed |
| EP-1261611-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077032-A1 | KARI Nanoparticle | TKT, PBK, KYAT1 | LMNA 2592/4885NFKB1 1087/4885TSHR 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.